EA201690129A1 - Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента - Google Patents

Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента

Info

Publication number
EA201690129A1
EA201690129A1 EA201690129A EA201690129A EA201690129A1 EA 201690129 A1 EA201690129 A1 EA 201690129A1 EA 201690129 A EA201690129 A EA 201690129A EA 201690129 A EA201690129 A EA 201690129A EA 201690129 A1 EA201690129 A1 EA 201690129A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sumo
activating enzyme
heteroarryl
inhibitor
compounds suitable
Prior art date
Application number
EA201690129A
Other languages
English (en)
Other versions
EA032577B1 (ru
Inventor
Мэттью О. Даффи
Дилан Б. Инглэнд
Чжигэнь Ху
Мицухиро Ито
Стивен П. Лэнгстон
Чарльз Макинтайр
Хиротаке Мизутани
Хе Сюй
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201690129A1 publication Critical patent/EA201690129A1/ru
Publication of EA032577B1 publication Critical patent/EA032577B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Описаны соединения формулы (I)или их фармацевтически приемлемые соли, где Y, Ra, Ra', Rc, Rf, X2, Rd, Rd', Re, Re' 2, m и G имеют значения, описанные в настоящем документе, и стереохимические конфигурации в положениях, отмеченных звездочками, указывают абсолютную конфигурацию, пригодные в качестве ингибиторов Sumo-активирующего фермента (SAE). Дополнительно представлены фармацевтические композиции, содержащие соединение согласно настоящему описанию, и способы применения указанных композиций при лечении пролиферативных, воспалительных, сердечно-сосудистых и нейродегенеративных заболеваний или расстройств.
EA201690129A 2013-07-02 2014-07-01 Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента EA032577B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361842097P 2013-07-02 2013-07-02
PCT/US2014/045129 WO2015002994A2 (en) 2013-07-02 2014-07-01 Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Publications (2)

Publication Number Publication Date
EA201690129A1 true EA201690129A1 (ru) 2016-06-30
EA032577B1 EA032577B1 (ru) 2019-06-28

Family

ID=52144279

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690129A EA032577B1 (ru) 2013-07-02 2014-07-01 Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента

Country Status (8)

Country Link
US (1) US9695154B2 (ru)
EP (1) EP3016934B1 (ru)
JP (1) JP6378759B2 (ru)
CN (1) CN105492429A (ru)
BR (1) BR112015032902A8 (ru)
CA (1) CA2916468C (ru)
EA (1) EA032577B1 (ru)
WO (1) WO2015002994A2 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
SG11201404757WA (en) 2012-02-17 2014-09-26 Millennium Pharm Inc Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物
CN106999479B (zh) 2014-07-01 2021-07-16 米伦纽姆医药公司 可用作sumo活化酶抑制剂的杂芳基化合物
KR101927375B1 (ko) 2016-04-20 2018-12-11 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN105670066A (zh) * 2016-04-22 2016-06-15 宁波硫华聚合物有限公司 橡胶促进剂活性剂氧化镁母胶粒及其制备方法
CN107586315B (zh) * 2016-07-08 2020-03-31 成都海创药业有限公司 一种嵌合分子
EP3490980A4 (en) * 2016-07-22 2020-04-15 Virginia Commonwealth University PRODRUG AND PROTECTED FORMS OF 5-HYDROXYMETHYLFURFURANAL (5-HMF) AND ITS DERIVATIVES
US20210161898A1 (en) * 2018-07-27 2021-06-03 Arcus Biosciences, Inc. Pyridone a2r antagonists
WO2020028525A1 (en) * 2018-07-31 2020-02-06 City Of Hope Sumo inhibitor compounds and uses thereof
WO2022159980A1 (en) * 2021-01-25 2022-07-28 Athos Therapeutics, Inc. Pharmaceutical compounds and methods of making and using the same
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
WO2024067676A1 (zh) * 2022-09-30 2024-04-04 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
WO2024097736A1 (en) * 2022-11-02 2024-05-10 Arcus Biosciences, Inc. Processes for preparing azolopyrimidine compounds
WO2024099438A1 (zh) * 2022-11-11 2024-05-16 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
CA2477795A1 (en) 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
EP1572709A3 (en) 2002-07-24 2005-11-23 PTC Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
US7078525B2 (en) 2002-09-04 2006-07-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE60313872T2 (de) 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20060276520A1 (en) 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
WO2005037845A1 (en) 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
WO2005051949A1 (ja) 2003-11-26 2005-06-09 Dainippon Sumitomo Pharma Co., Ltd. 新規縮合イミダゾール誘導体
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
DK1848718T3 (da) 2005-02-04 2012-08-27 Millennium Pharm Inc E1 aktiveringsenzymhæmmere
CA2624826A1 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
EA031335B1 (ru) * 2006-02-02 2018-12-28 Миллениум Фармасьютикалз, Инк. Производные пирролопиримидинов
JP5274460B2 (ja) * 2006-08-08 2013-08-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素のインヒビターとして有用なヘテロアリール化合物
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ES2602615T3 (es) 2007-06-12 2017-02-21 Achaogen, Inc. Agentes antibacterianos
WO2009082691A1 (en) 2007-12-21 2009-07-02 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
TWI409265B (zh) 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
AR072939A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidas con etenilo y su uso en el tratamiento de infecciones virales
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2737661C (en) 2008-09-23 2019-08-20 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN104016987A (zh) 2009-05-14 2014-09-03 米伦纽姆医药公司 氨基磺酸((1s,2s,4r)-4-{4-[(1s)-2,3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2,3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐
KR101906146B1 (ko) 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CN104592205A (zh) 2010-03-01 2015-05-06 Gtx公司 用于治疗癌的化合物
ES2823350T3 (es) 2010-07-29 2021-05-06 Rigel Pharmaceuticals Inc Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
MX2014002015A (es) * 2011-08-24 2014-03-27 Millennium Pharm Inc Inhibidores de la enzima activadora de nedd8.
JP2015502137A (ja) * 2011-10-07 2015-01-22 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅ１酵素変異体およびその用途
WO2013066729A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
SG11201404757WA (en) 2012-02-17 2014-09-26 Millennium Pharm Inc Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
RS59140B1 (sr) 2013-10-21 2019-09-30 Merck Patent Gmbh Heteroarilna jedinjenja kao inhibitori btk i njihova upotreba
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof

Also Published As

Publication number Publication date
EP3016934A2 (en) 2016-05-11
BR112015032902A8 (pt) 2019-12-24
JP2016523925A (ja) 2016-08-12
JP6378759B2 (ja) 2018-08-22
CA2916468C (en) 2019-07-23
EP3016934B1 (en) 2018-01-10
WO2015002994A2 (en) 2015-01-08
CA2916468A1 (en) 2015-01-08
EP3016934A4 (en) 2016-12-14
EA032577B1 (ru) 2019-06-28
US20160355504A1 (en) 2016-12-08
CN105492429A (zh) 2016-04-13
US9695154B2 (en) 2017-07-04
WO2015002994A3 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
EA201690129A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201891553A1 (ru) Ингибиторы syk
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
EA201790595A1 (ru) Пиримидиноны в качестве ингибиторов фактора xia
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
MX2015017964A (es) Inhibidores de bromodominio.
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201790661A3 (ru) Ингибиторы вируса гепатита c
EA201590661A1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201391288A1 (ru) Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201401062A1 (ru) Бициклические пиразиноновые производные
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU